Atlas Trials

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Clinical trial NCT05676710 · COMPLETED

Trial details

NCT number
NCT05676710
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Start date
2023-02-10
Primary completion
2024-01-30
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.